Yuri Weigel

Cooley advised Parse Biosciences on its $50 million Series C financing. Partner Sonya Erickson led the Cooley team advising Parse Biosciences, which develops single-cell sequencing products used by more than 1,000 labs worldwide.

Read more

Cooley advised Rodeo Therapeutics, a biopharmaceutical company that develops small molecule therapies, on its agreement to sell to Amgen, a leader in biotechnology-based human therapeutics, for $721 million. Partner Laura Medina led the Cooley team advising Rodeo. 

Read more

Cooley advised leading global IT services provider ConvergeOne on its agreement to combine with Forum Merger Corporation, allowing ConvergeOne to become a public company, with an anticipated initial enterprise value of approximately $1.2 billion. Cooley partners Mehdi Khodadad and John McKenna led the team advising ConvergeOne.

Seattle – Cooley advised Alder Biopharmaceuticals on its $80 million initial public offering. Alder is a Washington-based clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder is currently developing two lead product candidates: ALD403, an investigational monoclonal antibody for migraine, and Clazakizumab, an investigational monoclonal antibody for rheumatoid arthritis and other autoimmune indications, in collaboration with Bristol-Myers Squibb. The company now trades on the Nasdaq Global Stock Market under the symbol "ALDR."